INTRODUCTION

Liver cirrhosis is complicated by renal sodium retention, which leads, eventually, to the ascitic stage of clinical decompensation. Before ascites development, sodium retention already occurs despite normal or even increased glomerular filtration rate (GFR) (1-6). The tubular segment where increased sodium reabsorption occurs in pre-ascitic cirrhosis is still debated.

Animals with preascitic cirrhosis and sodium retention have normal fluid delivery from the proximal convoluted tubule to the Henle’s loop (7-10). The tubular segment where increased sodium reabsorption occurs in pre-ascitic cirrhosis is still debated.

DYNAMICS OF SODIUM RETENTION IN PREASCITIC CIRRHOTIC RATS ASSESSED THROUGH PARATHYROID HORMONE INJECTION

Extracellular Ca++ stimulates membrane-bound calcium-sensing receptors (CaRs). CaRs stimulation leads to PGE2-mediated decrease in protein content of Na’-K’-2Cl- co-transporters (BSC-1) in the thick ascending limb (TAL) of Henle’s loop and of aquaporin 2 (AQP2) water channels in collecting ducts. Parathyroid hormone (PTH) increases CaRs and decreases BSC-1 and AQP2 tubular content. To assess the Ca++-dependent diuretic system in preascitic cirrhosis, we evaluated renal function, hormonal status, PGE2 urinary excretion, and renal content of BSC-1 and CaRs in three groups of rats: control rats received s.c. 5% glucose solution; two groups of rats with CCl4-induced preascitic cirrhosis received either s.c. glucose solution or five s.c. doses of 10 mcg/Kg PTH (one dose every 12 hours) prior to study. Cirrhotic rats, when compared to controls, showed reduced urine volume and sodium excretion; moreover, western blot analysis revealed reduced CaRs and increased BSC-1 protein content in cirrhotic rat kidneys. S.c. administration of PTH normalized urine and sodium excretion in cirrhotic rats and also increased renal plasma flow, PGE2 urinary excretion, and free-water clearance. Finally, PTH reduced BSC-1 and augmented CaRs content in cirrhotic rat kidneys. In conclusion, in preascitic cirrhosis sodium retention is associated with down-regulation of renal CaRs and up-regulation of tubular Na’-K’-2Cl- co-transporters. PTH returns these biomolecular changes, along with sodium and urine excretions, to normality, suggesting that exaggerated sodium reabsorption occurs primarily in the Henle’s loop in preascitic cirrhosis.

Key words: liver cirrhosis, ascites, sodium, calcium, parathyroid hormone, calcium-sensing receptors, Henle’s loop, aldosterone
retention in pre-ascitic cirrhosis occurs in Ca++-sensitive segments of the nephron (i.e. in the Henle’s loop). The diuretic effect shown in calcium-loaded preascitic cirrhotic patients was attributed to stimulation of extracellular calcium/polyvalent cation-sensing receptors (CaRs) (14). This is reasonable because, in rats with experimental preascitic liver cirrhosis and sodium retention, stimulation of CaRs with calcimimetic agents returns sodium and free-water excretion to normality (28). In the kidney, CaRs are located mainly in the TAL of Henle’s loop and in the collecting duct (29). In the TAL of Henle’s loop, CaRs stimulation inhibits sodium-potassium-chloride co-transport and leads to increased natriuresis (24, 30-34).

PTH, calcium, and CaRs compose an actual Ca++-dependent diuretic system, the activity of which might be deranged in preascitic cirrhosis with sodium retention. We hypothesize that, in pre-ascitic cirrhosis, the Henle’s loop might be a key contributor to sodium retention. To dissect the actual contribution of Henle’s loop to sodium retention in rats with experimental preascitic cirrhosis, we have evaluated the renal biomolecular and functional effects that subcutaneous administration of PTH may cause through modulation of the content of CaRs and Na+-K+-2Cl– cotransporters (BSC-1) in renal tubules.

MATERIAL AND METHODS

Experiments in rats were performed in compliance with the procedures outlined in the Italian Ministry of Health guidelines (no. 86/609/EEC) and according to the Principles of Laboratory Animal Care (NIH no. 85-23, revised in 1985). The University of Torino ethics committee specifically approved this study.

Studies were performed on male adult Wistar rats with preascitic cirrhosis and related control animals (Harlan Italy, Udine, Italy). Both groups were fed ad libitum with standard chow and water. Preascitic cirrhosis was induced by carbon tetrachloride (CCl4) (Riedel de Haen, Sigma-Aldrich, Seelze, Germany) chronically administered by gavage twice weekly as described elsewhere (28, 35). Cirrhotic rats were studied 9 weeks after starting CCl4 administration, when cirrhosis was clearly developed (35) (Fig. 1). Control rats were studied following a similar period of standardized diet.

Groups of rats

Human PTH1-34 (Bachem Distribution Services GmbH, Weil am Rhein, Germany) was dissolved in 5% glucose solution (vehicle) and administered subcutaneously to ten cirrhotic rats (group G3) in five timely spaced doses (one dose every 12 hours for 2 days before the study day) of 0.5 ml vehicle containing 10 mcg/Kg PTH. Eight control rats (group G1) and ten cirrhotic rats (group G2) were injected subcutaneously with the same volumes of vehicle alone.

Study protocol

On the study day, the rats were anaesthetized as described elsewhere (36). Blood was sampled (time 0) by cardiac puncture (0.3 cc) and inulin (IN) 10% (w/v) (Laevosan-Gesellschaft, Linz/Donau, Austria) plus para-aminomellipurate (PAH) 20% (w/v) (Nephrotest, BAG GmbH, Munich, Germany) were administered into the caudal vein as a priming bolus (0.14 ml/kg and 0.03 ml/kg, respectively) followed by a continuous infusion of 0.09 ml/kg/h inulin and 0.025 ml/kg/h PAH for 150 min, in order to assess glomerular filtration rate (GFR) and renal plasma flow (RPF) at different times by means of their respective steady-state plasma clearances (CIN and CPAH) (28, 37, 38).

The steady state technique implies these advantages over the urine collection clearance method: catheterization of the bladder and exact timing of serum and urine samples are unnecessary, less analytical work is needed, and more urine is available for further testing (38).

After 90 min of IN and PAH infusions (i.e. when the steady-state plasma levels of IN and PAH were reached) (28, 37), laparotomy was performed, the urinary bladder was emptied, and a clamp was positioned on the urethral orifice. Cardiac blood was then sampled (time 1) to assess basal values of CIN and CPAH, and then vehicle alone was injected as a single bolus (1 ml) into the right femoral vein of all rats (groups G1-G3). Cardiac blood was then sampled (0.3 cc) at precise intervals (20 min) for 1 hour (times 2, 3 and 4) to measure plasma osmolality and concentrations of inulin, PAH, sodium, potassium, and calcium. At each blood withdrawal, the volume of blood withdrawn was replaced with an equal volume of i.v. saline (28). Blood samples withdrawn at time 4 (i.e. 60 min after the injection of vehicle) were also used to measure plasma concentrations of PTH, vasopressin (AVP), plasma renin activity (PRA), aldosterone (A), norepinephrine (N), aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin and total bilirubin. At time 4, after collecting from the bladder the urine produced during the 60 min after vehicle administration, rats were killed by exsanguination through the aorta. This urine was then used to measure its osmolality and the excretion of sodium, potassium, and PGE2.

CaRs and BSC-1 protein concentrations in rat kidneys

Membrane fractions were prepared from kidneys removed from five rats in each experimental group (G1-G3) and the total protein content was assessed using Bradford Assay as described previously (28). Equal amounts of proteins (30 µg) were separated by SDS-PAGE and electrotransferred on nitrocellulose membrane (GE-Healthcare Europe, Milano, Italy). Membranes were probed with rabbit anti-CaRs (PAI-934, ABR Affinity BioReagents, Golden, CO, USA) and rabbit-anti BSC-1 (NKCC21-A, Alpha Diagnostic International, San Antonio, TX, USA) primary antibodies, followed by incubation with anti-rabbit IgG/HRP-conjugated secondary antibody (BioRad, Hercules, CA, USA).

Protein bands were detected with Clarity Western ECL substrate (BioRad) and quantified by densitometry using analytic software (Quantity-One, Bio-Rad). Results were normalized with respect to β-actin densitometric value.

Kidney CaRs and BSC-1 indirect immunofluorescence

Indirect immunofluorescence was performed in a humidified chamber at room temperature, essentially as described elsewhere (28, 39), on kidney cryostat sections (6 µm thick). Mouse monoclonal anti-CD31, an endothelial marker (BD-Pharmingen, Erembodegem, Belgium), and rabbit polyclonal anti-CaRs and anti-BSC-1 primary antibodies were used (28, 40).

Plasma and urine analyses

Plasma and urinary concentrations of electrolytes, and IN and PAH concentrations in plasma were measured as described elsewhere (41, 42). AVP and PTH systemic concentrations were measured on EDTA-plasma by RIA (Buhmann Laboratories AG, Postfach, Switzerland). PRA was measured using RIA for angiotensin I (Renin Maia Kit, Biodata, Rome, Italy). Aldosterone was evaluated by RIA (Coat-A-Count Aldosterone kit, Diagnostic Products Corporation, Los Angeles, CA, USA), and norepinephrine was measured as described elsewhere (43,
Urine samples were assayed for PGE\(_2\) concentrations by ELISA (Neogen, Lexington, KY, USA). Plasma AST, ALT, albumin and total bilirubin levels were determined by means of automated Roche/Hitachi Cobas equipment.

**Calculations**

Sodium clearance (CNa) and potassium clearance (CK) were calculated through the formula:

\[ Cx = \frac{(U-x x V)}{P-x} \]

where \(U-x\) is the urinary concentration of \(x\), \(P-x\) is the plasma concentration of \(x\), and \(V\) is the urinary output (ml/min).

Inulin clearance (CIN) and para-aminohippurate clearance (CPAH) were calculated through the steady-state plasma clearance formula as:

\[ Cx = \frac{\text{Infusion rate} (x)}{\text{ssP-x}} \]

where \(\text{ssP-x}\) is the steady-state plasma concentration of \(x\).

CIN and CPAH were taken as measures of GFR and RPF (37, 38). Filtered sodium load (FINa) was derived, following Boer et al. (45), as:

\[ \text{FINa} = \text{Sodium plasma concentration} (P-Na) x \text{CIN} \]

Fractional sodium excretion (FENa) and fractional potassium excretion (FEK) were calculated, respectively, from the ratios of CNa and CK to CIN x 100.

Free-water clearance (F-WCl) was calculated, following Rose and Post (46), through the formula:

\[ \text{F-WCl} = V – \text{Cosm} \]

where \(V\) is the urinary output (ml/min); \(\text{Cosm}\) is the osmolar clearance, which was computed via the usual formula:

\[ \text{Cosm} = \frac{Uosm x V}{Posm} \]

where \(Uosm\) and \(Posm\) are urine and plasma osmolalities, respectively.

Finally, in order to evaluate aldosterone function on the distal tubular nephron, the trans-tubular concentration ratio of potassium in the cortical collecting duct (TTKR) was calculated according to the following formula (47, 48):

\[ \text{TTKR} = \frac{[K^+]_{\text{urine}}}{[K^+]_{\text{plasma}}} \]

This parameter provides a semiquantitative reflection of the ratio of \([K^+]\) in the tubule fluid to that in the plasma of the adjacent vessels in the cortical collecting duct, an aldosterone-dependent segment of the tubular nephron.

All renal function parameters were derived by computing the mean of three determinations of osmolality, inulin, PAH, sodium, potassium, and calcium in plasma during the 60 min urine collection period (blood sampling times 2, 3, and 4).

**Morphological liver studies**

Livers were removed from all rats receiving CCl\(_4\), and hepatic tissue samples for light microscopy were placed in buffered 4% formaldehyde solution (pH 7.4). The sections were stained with hematoxylin and eosin to assess fibrosis. Silver-impregnated liver sections were used to observe portal-central or central-central bridging fibrosis.

**Statistical analysis**

Results are expressed as means ± S.D. All comparisons among groups of rats were made by one-way ANOVA test, followed by the Bonferroni test. The analyses were processed by the SPSS® 13.0 software (Chicago, USA), using a significance level of 5%.

**RESULTS**

**Morphological liver studies**

Micronodular cirrhosis with hepatocellular necrosis and steatosis was found in all the livers removed from CCl\(_4\)-treated rats (Fig. 1).
A comparative analysis of the membrane fraction of renal tissue homogenate showed that CaRs protein content was significantly reduced in cirrhotic vs. control animals, and protein content of BSC-1 was significantly increased in cirrhotic rats (Fig. 2). Protein content of CaRs and BSC-1 returned to control values in cirrhotic rats pre-treated with s.c. PTH (Fig. 2). CaRs- and BSC-1-positive tubular cells were identified in the TAL of Henle’s loop of normal and cirrhotic rat kidneys, as shown previously (28). CaRs were located in the sub-endothelial layers of kidney medullary arterioles of cirrhotic rats (Fig. 3). In control and cirrhotic rats, CaRs were also located in medullary collecting ducts, as previously shown (28).

**Content and immunostaining of renal CaRs and BSC-1**

**Hormonal status (Table 1)**

Treatment with s.c. PTH had no effects on PRA, A, AVP, and N plasma levels in cirrhotic animals. PTH-treated cirrhotic rats (G3) had significantly higher plasma PTH concentrations and higher urinary excretion rate of PGE$_2$ when compared to the untreated cirrhotic group (G2). Increased PGE$_2$ urinary excretion is expected when hypercalcemia stimulates CaRs.

**Renal function (Table 2)**

Compared to control animals (G1), cirrhotic rats belonging to G2 showed reduced urine volume and absolute and fractional excretions of sodium. Free-water clearance was lower in cirrhotic animals than in control rats, and RPF was higher in cirrhotic rats than in controls, at baseline. In cirrhotic rats, s.c. PTH significantly improved urine volume, absolute and fractional excretion of sodium and potassium, which means that the TAL of Henle’s loop is affected, free-water clearance, which means the collecting duct is affected, and renal plasma flow. The values of TTKR were equal in control and cirrhotic rats. PTH did not affect GFR in cirrhotic rats, and, as expected, PTH significantly increased plasma Ca$^{++}$ levels in cirrhotic rats.

**DISCUSSION**

In experimental preascitic cirrhosis, retention of sodium and fluid is associated with increased contents of Na$^+$-K$^+$-2Cl$^-$ cotransporters in the TAL of Henle’s loop. Sodium retention is also associated with decreased contents of CaRs (the targets of extracellular Ca$^{++}$ and calcimimetic drugs) in Henle’s loop and
collecting ducts (Fig. 2). PTH administration restores the physiological protein content of CaRs and BSC-1, and this increases urinary sodium and water excretion of cirrhotic rats up to the values measured in controls (Table 2). It is reasonable to say that perhaps little sodium retention would occur in this early stage of experimental preascitic cirrhosis if tubular content of CaRs and, mostly, BSC-1 were normal.

In this study, aldosterone function was assessed through the computation of the trans-tubular concentration ratio of potassium in the cortical collecting duct (TTKR) (47, 48). TTKR, which reflects the ratio between K⁺ concentrations in the tubule fluid and in the plasma of the adjacent vessels, was equal in control and cirrhotic rats. This indicates that mineralocorticoid-mediated hyperstimulation of tubular sodium re-absorption in exchange with potassium secretion has not occurred yet at this early stage of compensated cirrhosis. In other words, increased sodium re-absorption in the Henle’s loop precedes aldosterone-dependent sodium retention.

Subtle interactions between PTH systemic concentrations and renin-angiotensin-aldosterone system (RAAS) activity have been repeatedly described. For instance, infusion of angiotensin II or aldosterone causes significant increase in the rate of PTH secretion in human health and disease (49, 50); more importantly, in healthy human subjects short-term PTH infusion stimulates renin release and aldosterone secretion (51, 52), but also increases the rate of renal hydroxilation of vitamin D, which, in turn, may negatively regulate renin expression and RAAS activity (50, 53). On the whole, in this study PTH administration to cirrhotic rats caused a slight, statistically insignificant, increase of both PRA and plasma aldosterone, along with the natriuretic effects due to BSC-1 down-regulation. Once again, this underlines the modest, if any, role of aldosterone in the control of sodium handling in this stage of cirrhotic disease.

PTH exclusive capacity to down-regulate BSC-1 and to up-regulate CaRs was extremely useful to ascertain the dynamic connections between the expression of the above proteins and the patterns of tubular sodium handling. No other hormone can modulate expression of CaRs and sodium channels in the tubular nephron so promptly. Moreover, the choice of experimental animal models is the only available option to study the dynamics of expression of tubular sodium channels since it would be unethical and dangerous to submit human cirrhotic patients to repeated administrations of PTH.

This dynamic approach led to the conclusion that excessive sodium retention takes place in the Henle’s loop of preascitic cirrhotic rats. Previous literature had already suggested the existence of such a mechanism of sodium retention in cirrhotic rats (8, 21, 22, 28) based on the following findings: i) the TAL of Henle’s loop is hypertrophic; ii) the natriuretic response to furosemide and the medullary interstitial sodium concentration are increased. Moreover, in patients with compensated cirrhosis,
the natriuretic responses to intravenous calcium loading are larger than in controls (14) and aldosterone-independent sodium retention takes place after the proximal convoluted tubule (6, 54).

There are analogies between the effects of PTH and intravenous calcium loading (14), and this indicates that the results presented in this study depend on the systemic hypercalcemia induced by PTH. This also means that the stimulation of CaRs in Henle’s loop and collecting duct, as recently shown with the use of calcimimetic agents (28), represents the actual trigger leading to the normalization of sodium and fluid excretion in experimental preascitic cirrhosis.

Following the studies of Wang and associates (24), we chose to inject a moderate dose of PTH to avoid early death of cirrhotic rats due to excessive hypercalcemia. Yet this PTH dose increased the urinary excretion of PGE₂ (Table 1), the second messenger generated after specific stimulation of CaRs (32), and caused natriuresis and aquarexis (Table 2).

PTH injection in cirrhotic rats also caused a considerable renal vasodilatation (Table 2). This was due to the large amount of CaRs located in the sub-endothelial layers of renal arterioles of the outer medulla (Fig. 3). This renal vasodilatation might be useful in the advanced stages of cirrhosis, when renal vasoconstriction leads to reduced GFR (55, 56).

Our results may also suggest a method of investigation of two apparently unrelated processes: the hypercalciuria of mineralocorticoid escape (57) and the tubular pattern of sodium handling in chronic renal failure (CRF).

Mineralocorticoid escape indicates the occurrence of reduced reabsorption of sodium in aldosterone-independent tubules when the kidney faces chronically elevated levels of plasma aldosterone. The hypercalciuria that coincides with aldosterone escape might trigger decreased tubular sodium re-absorption in the Henle’s loop and compensatory natriuresis. Further on, increased expression of CaRs in peripheral blood monocytes of patients with diabetes mellitus and peripheral artery disease (58) might mean that this calcium-dependent homeostatic mechanism is already somehow operative in that clinical setting.

The already established association of CRF and systemic down-regulation of CaRs (59, 60), suggests the explanation of a common clinical observation: CRF is characterized by low GFR and increased fractional excretion of sodium, while functional renal failure (FRF) in liver cirrhosis is characterized by low GFR and avid tubular sodium retention with low fractional sodium excretion. The secondary hyperparathyroidism occurring in CRF (61), but not in cirrhotic FRF, might contribute to the completely different tubular handling of sodium that is found in these two diseases.

In conclusion, in sodium-retaining preascitic cirrhotic rats we confirmed increased content of Na⁺-K⁺-2Cl⁻ cotransporters in the TAL of Henle’s loop and down-regulation of renal CaRs, the receptors that mediate Ca++-dependent diuresis. The injection of PTH restored the physiological content of these tubular proteins and returned renal sodium handling to normal. In this context, the action of parathyroid hormone-related peptide (PTHrP) (62) or exogenous compounds that affects both PTH and renal tubular function (e.g. genistein) (63) would be worth some experimental focus.

The findings described in this study represent experimental evidence to support the hypothesis that sodium retention in preascitic cirrhosis occurs first in the TAL of Henle’s loop and later in aldosterone-dependent tubular segments. A third mechanism of sodium retention, increased reabsorption in the proximal convoluted tubule, is operative in preascitic cirrhotic patients while standing (11, 12). This paves the way to potential new strategies of prevention of ascites: orally active calcimimetic agents (28, 61) or oral calcium supplement (14), due to their diuretic, aquaretic and renal vasodilating properties.

Table 1. Hormonal plasma and urine determinations in different groups of rats.

<table>
<thead>
<tr>
<th></th>
<th>G1 (n= 8)</th>
<th>G2 (n= 10)</th>
<th>G3 (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma AVP (pg/ml)</td>
<td>98 ± 57</td>
<td>104 ± 32</td>
<td>85 ± 41</td>
</tr>
<tr>
<td>PRA (ng/ml/h)</td>
<td>20 ± 1</td>
<td>18 ± 2</td>
<td>21 ± 8</td>
</tr>
<tr>
<td>Plasma A (ng/ml)</td>
<td>2.1 ± 1.9</td>
<td>2.9 ± 3.1</td>
<td>3.1 ± 1.8</td>
</tr>
<tr>
<td>Plasma N (pg/ml)</td>
<td>118 ± 71</td>
<td>142 ± 91</td>
<td>132 ± 64</td>
</tr>
<tr>
<td>Plasma PTH (pg/ml)</td>
<td>1.8 ± 0.8</td>
<td>2.0 ± 0.4</td>
<td>3.6 ± 0.5a</td>
</tr>
<tr>
<td>Urinary PGE₂ (ng/h)</td>
<td>2.0 ± 1.3</td>
<td>1.5 ± 0.1</td>
<td>6.9 ± 2.2a</td>
</tr>
<tr>
<td>Plasma AST (U/ml)</td>
<td>31 ± 21</td>
<td>52 ± 27b</td>
<td>59 ± 33b</td>
</tr>
<tr>
<td>Plasma ALT (U/ml)</td>
<td>38 ± 21</td>
<td>61 ± 22b</td>
<td>65 ± 38b</td>
</tr>
<tr>
<td>Plasma albumin (g/dl)</td>
<td>3.7 ± 1.2</td>
<td>2.6 ± 0.9b</td>
<td>2.4 ± 0.7b</td>
</tr>
<tr>
<td>Plasma bilirubin (mg/dl)</td>
<td>0.2 ± 0.04</td>
<td>2.8 ± 0.03b</td>
<td>3.0 ± 0.09g</td>
</tr>
</tbody>
</table>

Data are means ±S.D. G1: control rats; G2: cirrhotic rats; G3: cirrhotic rats receiving s.c. PTH. *P<0.05 vs. G2; g P<0.05 vs. G1 (one-way ANOVA, followed by the Bonferroni test).
might represent further means to delay ascites development when administered chronically in patients with compensated cirrhosis.

**Abbreviations:** A: aldosterone; AQP2: aquaporin 2; AST: aspartate aminotransferase; ALT: alanine aminotransferase; AVP: vasopressin; BSC-1: Na⁺-K⁺-2Cl⁻ cotransporter; Cl⁻: carbon tetrachloride; CaRs: extracellular calcium/polyvalent cation-sensing receptors; CIN: inulin clearance; CK: potassium clearance; CNA: sodium clearance; CPAH: para-aminohippurate clearance; CRF: chronic renal failure; FENa: fractional excretion of potassium; FENa: fractional excretion of sodium; FlNa: filtered sodium load; FRF: functional renal failure; F-WCl: free-water clearance; GFR: glomerular filtration rate; IN: inulin; N: norepinephrine; PAH: para-aminohippurate; PRA: plasma renin activity; PTH: parathyroid hormone; PTHrP: parathyroid hormone-related peptide; RAAS: renin-angiotensin-aldosterone-system; RPF: renal plasma flow; SDS: sodium dodecyl sulfate; TAL: thick ascending limb of Henle’s loop; TTKR: trans-tubular concentration ratio of potassium in the cortical collecting duct.

**Acknowledgements:** Supported in part by grants from the Ministry of University and of Scientific Research (60%), 2008. No additional external funding was received for this study. The authors have no competing interest to disclose. This study was presented orally at the 2010 annual meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.

**Authors’ contributions:** G.S. and M.P. contributed to study concept and design, study supervision as well as analysis and interpretation of data and drafting of the manuscript. M.A. and R.M. contributed to acquisition of data as well as to analysis and interpretation of data (including statistical analysis). All authors were involved in writing and in critical revision of the final manuscript.

**Conflict of interests:** None declared.

**REFERENCES**


---

**Table 2. Renal function data.**

<table>
<thead>
<tr>
<th></th>
<th>G1 (n= 8)</th>
<th>G2 (n= 10)</th>
<th>G3 (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urine volume (ml/h)</strong></td>
<td>0.8 ± 0.1</td>
<td>0.5 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.0 ± 0.3&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Natriuresis (microM/h)</strong></td>
<td>140 ± 11</td>
<td>112 ± 4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>190 ± 7&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>FENa (%)</strong></td>
<td>2.2 ± 0.5</td>
<td>1.5 ± 0.08&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.6 ± 0.09&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Kaliuresis (microM/h)</strong></td>
<td>130 ± 5</td>
<td>109 ± 3</td>
<td>170 ± 6&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>FEK (%)</strong></td>
<td>9.1 ± 3.3</td>
<td>7.1 ± 2.9</td>
<td>11.4 ± 2.2&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Cosm (ml/h)</strong></td>
<td>0.22 ± 0.08</td>
<td>0.11 ± 0.07&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.24 ± 0.04&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>F-WCl (ml/h)</strong></td>
<td>0.58 ± 0.07</td>
<td>0.43 ± 0.03&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.78 ± 0.12&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Uosm (mOsm/Kg H₂O)</strong></td>
<td>1188 ± 334</td>
<td>1399 ± 277&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1246 ± 108&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>GFR (ml/min)</strong></td>
<td>0.83 ± 0.33</td>
<td>1.0 ± 0.71</td>
<td>0.88 ± 0.77</td>
</tr>
<tr>
<td><strong>RPF (ml/min)</strong></td>
<td>0.98 ± 0.33</td>
<td>1.21 ± 0.33&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.88 ± 0.5&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Plasma Na⁺ (mEq/l)</strong></td>
<td>141.3 ± 4.5</td>
<td>143.1 ± 4.1</td>
<td>147.7 ± 5.2</td>
</tr>
<tr>
<td><strong>Plasma K⁺ (mEq/l)</strong></td>
<td>4.3 ± 1</td>
<td>4.6 ± 0.6</td>
<td>4.0 ± 0.7</td>
</tr>
<tr>
<td><strong>Plasma Ca++ (mM/l)</strong></td>
<td>2.3 ± 0.6</td>
<td>2.4 ± 0.8</td>
<td>3 ± 1&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>TTKR</strong></td>
<td>9.8 ± 3.9</td>
<td>10.1 ± 4.2</td>
<td>9.9 ± 3.7</td>
</tr>
</tbody>
</table>

Data are means ± S.D. G1: control rats; G2: cirrhotic rats; G3: cirrhotic rats receiving s.c. PTH. *P<0.05 vs. G1; b P<0.05 vs. G2 (one-way ANOVA, followed by the Bonferroni test).


Received: May 29, 2014
Accepted: September 12, 2014

Author’s address: Dr. Giovanni Sansoe, Division of Gastroenterology, Gradenegro Hospital, 10 Corso Regina Margherita, 10153 Torino, Italy.
E-mail address: giovannisan@iol.it